Common Prostate Drug May Slow Progression of Parkinson, Researchers Say – AJMC.com Managed Markets Network

Terazosin, a drug used to treat enlarged prostate, may also be able to slow the progression of Parkinson disease.

The finding is the result of a collaboration involving researchers in China and at the University of Iowa (UI), combining observations from animal experiments with information from clinical databases regarding men taking the drug.

Lei Liu, PhD, at Capital Medical University in Beijing, China, found that terazosin could block cell death. Using toxin-induced and genetic PD models in mice, rats, flies, and induced pluripotent stem cells, the drug increased brain adenosine triphosphate levels and slowed or prevented neuron loss if it was given before the onset of cell death. In addition, the drug could slow or stop neurodegeneration, even if treatment was delayed until after neurodegeneration had started to develop. Liu's team discovered that the cell-protective activity was due to terazosin's ability to activate phosphoglycerate kinase 1 (PGK1), an enzyme critical for cellular energy production.

Researchers then probed databases looking at patients who took terazosin and found slower disease progression, decreased PD-related complications, and a reduced frequency of PD diagnoses.

This suggests that in patients taking terazosin and related drugs, enhanced PGK1 activity and increased glycolysis may slow neurodegeneration in PD.

"When we tested the drug in various different animal models of PD, they all got better. Both the molecular changes in the brain associated with cell death and the motor coordination in the animals improved," said Liu, a professor in the Beijing Institute for Brain Disorders, in a statement.

Nandakumar Narayanan, MD, PhD, a UI neurologist, and Jordan Schultz, PharmD, UI assistant professor of psychiatry, examined the Parkinson's Progression Markers Initiative database, which is sponsored by The Michael J. Fox Foundation for Parkinson's Research. The data showed that men with PD who were taking terazosin had reduced rates of progressive motor disability compared to men with PD who were taking a different drug, tamsulosin, for enlarged prostate.

While tamsulosin is also used to treat benign prostatic hyperplasia, unlike terazosin, it does not have any effect on the PGK1 enzyme, making ita good control.

Only 13 men were identified who were taking terazosin or 1 of 2 similar drugs that also activate the PGK1 enzyme, compared with 293 men with PD who were either taking tamsulosin or were not taking any of these drugs. While the differences in motor decline between the 2 groups were statistically significant, the team looked to confirm the findings using the larger IBM Watson/Truven Health Analytics MarketScan Database, which includes de-identified records of more than 250 million people.

From there, researchers identified 2880 Parkinson's patients taking 1 of the 3 drugs that target PGK1 (terazosin, doxazosin, or alfusin) and a comparison group of 15,409 PD patients taking tamsulosin. Using medical codes to track PD-related diagnoses and hospital or clinic visits for all the patients, the data suggested that under real world conditions, terazosin and related drugs reduce the signs, symptoms, and complications of PD. Relative to patients with PD taking tamsulosin, those on terazosin or the 2 other drugs had reduced clinic and hospital visits for motor symptoms (relative risk [RR] 0.77; 95% CI, 0.700.84), nonmotor symptoms (RR 0.78; 95% CI, 0.730.83), and PD complications (RR 0.76; 95% CI, 0.710.82).

Patients using terazosin also had a reduced risk of a PD diagnosis, the researchers said.

Reference

Cai R, Zhang Y, Simmering JE, et al. Enhancing glycolysis attenuates Parkinsons disease progression in models and clinical databases [published online September 16, 2019].J Clin Invest. doi: 10.1172/JCI129987.

See the article here:
Common Prostate Drug May Slow Progression of Parkinson, Researchers Say - AJMC.com Managed Markets Network

Stem Cell-Derived Cells Market to Record an Exponential CAGR by 2025 – NewsVarsity

Stem cell-derived cells are ready-made human induced pluripotent stem cells (iPS) and iPS-derived cell lines that are extracted ethically and have been characterized as per highest industry standards. Stem cell-derived cells iPS cells are derived from the skin fibroblasts from variety of healthy human donors of varying age and gender. These stem cell-derived cells are then commercialized for use with the consent obtained from cell donors. These stem cell-derived cells are then developed using a complete culture system that is an easy-to-use system used for defined iPS-derived cell expansion. Majority of the key players in stem cell-derived cells market are focused on generating high-end quality cardiomyocytes as well as hepatocytes that enables end use facilities to easily obtain ready-made iPSC-derived cells. As the stem cell-derived cells market registers a robust growth due to rapid adoption in stem cellderived cells therapy products, there is a relative need for regulatory guidelines that need to be maintained to assist designing of scientifically comprehensive preclinical studies. The stem cell-derived cells obtained from human induced pluripotent stem cells (iPS) are initially dissociated into a single-cell suspension and later frozen in vials. The commercially available stem cell-derived cell kits contain a vial of stem cell-derived cells, a bottle of thawing base and culture base.

The increasing approval for new stem cell-derived cells by the FDA across the globe is projected to propel stem cell-derived cells market revenue growth over the forecast years. With low entry barriers, a rise in number of companies has been registered that specializes in offering high end quality human tissue for research purpose to obtain human induced pluripotent stem cells (iPS) derived cells. The increase in product commercialization activities for stem cell-derived cells by leading manufacturers such as Takara Bio Inc. With the increasing rise in development of stem cell based therapies, the number of stem cell-derived cells under development or due for FDA approval is anticipated to increase, thereby estimating to be the most prominent factor driving the growth of stem cell-derived cells market. However, high costs associated with the development of stem cell-derived cells using complete culture systems is restraining the revenue growth in stem cell-derived cells market.

Browse Full Report at https://www.persistencemarketresearch.com/market-research/stem-cell-derived-cells-market

The global Stem cell-derived cells market is segmented on basis of product type, material type, application type, end user and geographic region:

Segmentation by Product Type Stem Cell-Derived Cell Kits Stem Cell-Derived Definitive Endoderm Cell Kits Stem Cell-Derived Beta Cell Kits Stem Cell-Derived Hepatocytes Kits Stem Cell-Derived Cardiomyocytes Kits Accessories

Segmentation by End User Hospitals Research and Academic Institutions Biotechnology and Pharmaceutical Companies Contract Research Organizations/ Contract Manufacturing Organizations

Get Sample Copy of this report at https://www.persistencemarketresearch.com/samples/28780?source=atm

The stem cell-derived cells market is categorized based on product type and end user. Based on product type, the stem cell-derived cells are classified into two major types stem cell-derived cell kits and accessories. Among these stem cell-derived cell kits, stem cell-derived hepatocytes kits are the most preferred stem cell-derived cells product type. On the basis of product type, stem cell-derived cardiomyocytes kits segment is projected to expand its growth at a significant CAGR over the forecast years on the account of more demand from the end use segments. However, the stem cell-derived definitive endoderm cell kits segment is projected to remain the second most lucrative revenue share segment in stem cell-derived cells market. Biotechnology and pharmaceutical companies followed by research and academic institutions is expected to register substantial revenue growth rate during the forecast period.

North America and Europe cumulatively are projected to remain most lucrative regions and register significant market revenue share in global stem cell-derived cells market due to the increased patient pool in the regions with increasing adoption for stem cell based therapies. The launch of new stem cell-derived cells kits and accessories on FDA approval for the U.S. market allows North America to capture significant revenue share in stem cell-derived cells market. Asian countries due to strong funding in research and development are entirely focused on production of stem cell-derived cells thereby aiding South Asian and East Asian countries to grow at a robust CAGR over the forecast period.

Some of the major key manufacturers involved in global stem cell-derived cells market are Takara Bio Inc., Viacyte, Inc. and others.

The report covers exhaustive analysis on: Stem cell-derived cells Market Segments Stem cell-derived cells Market Dynamics Historical Actual Market Size, 2014 2018 Stem cell-derived cells Market Size & Forecast 2019 to 2029 Stem cell-derived cells Market Current Trends/Issues/Challenges Competition & Companies involved Stem cell-derived cells Market Drivers and Restraints

Regional analysis includes North America Latin America Europe East Asia South Asia Oceania The Middle East & Africa

Report Highlights: Shifting Industry dynamics In-depth market segmentation Historical, current and projected industry size Recent industry trends Key Competition landscape Strategies of key players and product offerings Potential and niche segments/regions exhibiting promising growth A neutral perspective towards market performance

Get Full Report Access of this report at https://www.persistencemarketresearch.com/checkout/28780?source=atm

More:
Stem Cell-Derived Cells Market to Record an Exponential CAGR by 2025 - NewsVarsity

Automated Large-Scale Production of Retinal Organoids – Advanced Science News

Share

Share

Email

The retina is the innermost layer in the eye and is responsible for converting light energy to electrical signals which are transmitted to the brain and are processed into an image. It consists of six major cell types which are organized in a specific laminated manner to allow it to function properly.

Non-treatable visual impairment caused by the degeneration of the retina is increasingly affecting millions of people worldwide. However, there are currently no adequate in vivo or in vitro models that would allow the study of human retinal development and pathological processes in a disease state. Additionally, most of drug screening is currently performed on model animals that do not recapitulate human physiology and retinal function.

The advent of human induced pluripotent stem cells and an increased understanding of human retinal development has allowed scientists to develop a method for generating retinal organoids, which are miniature synthetic counterparts to human retina.

In a recent study published in Current Protocols in Stem Cell Biology, Professor Majlinda Lako and co-workers describe a method for large-scale production of retinal organoids that contain all major retinal cell types.

The study offers an organoid-based system, which is relevant to human physiology and has a wide range of applications, including drug testing, disease modelling, cell therapy, and in the study of human retina development.

More:
Automated Large-Scale Production of Retinal Organoids - Advanced Science News

How a Centuries-Old Sculpting Method Is Helping 3D Print Organs With Blood Vessels – Singularity Hub

Blood vessels are the lifeline of any organ.

The dense web of channels, spread across tissues like a spider web, allow oxygen and nutrients to reach the deepest cores of our hearts, brains, and lungs. Without a viable blood supply, tissues rot from the inside. For any attempt at 3D printing viable organs, scientists have to tackle the problem of embedding millions of delicate blood vessels throughout their creation.

Its a hideously hard problem. Although blood vessels generally resemble tree-like branches, their distribution, quantity, size, and specific structure vastly differs between people. So far, the easiest approach is to wash out cells from donated organs and repopulate the structure with recipient cellsa method that lowers immunorejection after transplant. Unfortunately, this approach still requires donor organs, and with 20 people in the US dying every day waiting for an organ transplant, its not a great solution.

This week, a team from Harvard University took a stab at the impossible. Rather than printing an entire organ, they took a Lego-block-like approach, making organ building blocks (OBBs) with remarkably high density of patient cells, and assembled the blocks into a living environment. From there, they injected a sacrificial ink into the proto-tissue. Similar to pottery clay, the ink hardens upon curingleaving a dense, interconnected 3D network of channels for blood to run through.

As a proof of concept, the team printed heart tissue using the strategy. Once the block fused, the lab-made chunk of heart could beat in synchrony and remained healthy for at least a week.

The technology, SWIFT (an eyebrow-raising backcronym of sacrificial writing into functional tissue), is a creative push into a new generation of 3D biofabrication. Although OBBs have been around, the team explained, little attention was previously paid to putting the Lego pieces together with blood vessels.

This is an entirely new paradigm for tissue fabrication, said study author Dr. Mark Skylar-Scott. The focus is on vessels, which will support 3D printed living tissue that may eventually be used to repair damaged parts of a natural body, or even replace entire human organs with lab-grown versions, he added.

[Its] beautiful work, commented tissue engineer Dr. Jordan Miller at Rice University, who was not involved in the study.

SWIFT straddles two wildly diverse fields across centuries: organoids and 15th-century lost-wax sculpturing.

Youve heard of organoids. Often dubbed mini-organs, these lentil-sized blobs of tissue remarkably mimic particular aspects of entire organsbrain organoids, for example, show the characteristic nerve cell types of firings of a preemie baby. The cellular inhabitants that make up organoids are what especially caught the teams attention: most are grown from induced pluripotent stem cells (iPSCs), which are often skin cells de-aged in a way that they can develop into almost any cell type with a little chemical prodding.

Because organoids are built from a patients own cells, theyre completely compatible with the host for an immune standpoint. That particular strength caught the teams attention: organoids, they reasoned, make the ideal OBBor Lego piecesto biomanufacture patient- and organ-specific tissues with all the desired properties.

For example, the team explained, organoids are packed with a high density of cells, which is usually hard to achieve with traditional 3D tissue printing. Under the right conditions, they also develop similarly to real organs in terms of cellular composition and microarchitecture to support functionfor about a year. Without a blood vessel network, all organoids die.

Heres where lost-wax technique comes in.

First, a very brief explainer. Throughout the Renaissance, the majority of Italian sculptors used the technique to fabricate bronze statues. In the simplest method, a statuette is first modeled in beeswax and covered in potters clay. Once dried, the assembly is heatedthe clay is fired into ceramics, and the wax melts and flows away (hence, lost). Once cooled, the entire project is now a hollow ceramic mold, through which the artist can pour in molten metal.

Now, replace beeswax with sacrificial bio-ink, and thats pretty much how SWIFT carves out its intricate tunnels of blood vessels.

The entire fabrication process is two main steps. The team first grew hundreds of thousands of proto-organoids inside culture dishes. These tiny blobs are so small they dont yet need to be churned inside a bioreactor, but theyre mightily packed with roughly 200 million cells every milliliterabout the bottom bit of a teaspoon. These make up the techniques building blocks, or OBBs.

Next, roughly 400,000 OBBs are mixed with a dense, gel-like liquid with the consistency of mayonnaise at a low temperature. The liquid is filled with collagen, a protein that keeps our skin elastic, and other synthetic versions. The OBBs are now somewhat suspended inside the gel-like matrix, which is ideally suited for creating vascular channels, the team said. Altogether, the organoids and gel are compacted into a density similar to human tissue, making up the raw material for further sculpting.

Now the fun second step. Using a 3D printer, the team moved a tiny nozzle containing both harmless red ink and gelatin into the mixture, depositing both in a pre-programmed manner. In this way, the team was able to draw intricate branch-like patterns into the organoid-gel mixture. Similar to squeezing frosting out of a bag, the team was able to adjust the diameter of the gelatin ink by nearly two-fold, mimicking the usual structure of blood vesselsthick main channels that increasingly become tinier.

Once the network was fully printed, they then gently heated the mixture to body temperature. The matrix stiffens, and the gelatin inkacting like Jello left under the sun for too longmelts and is washed away. What remains is a network of OBBS, or organoids, linked with a vascular structure that can now be filled with blood.

As a proof of concept, the team went straight for the heartcardiac tissue, that is. They repeated the steps using heart-derived cells, and kept the resulting chunk of heart, a little bigger than half an inch inside a chamber, filled with a nutritious, oxygen-rich bath.

Within a week, individual organoids embedded inside the gel fused together into a collective: the tissue was able to contract almost 50 percent better than immediately after printing, and the beating rhythm synchronized, suggesting that the lab-grown tissue had further matured.

The tissue even reacted similarly to a normal heart. When the team infused a drug that increases heart rate into those printed vessels, the tissue doubled in its heartbeat. Similarly, drugs that normally decrease heart muscle contraction also worked on the mini-heart. As a final proof of concept demo, the team printed a chunk of heart tissue with a branch of the coronary arterya main blood vessel branch that normally wraps the heart.

The new study is hardly the first try at printing organs with blood vessels. Miller, for example, biomanufactured a hydrogel that mimicked a lung air sac earlier this May. Layer by layer, the precise anatomy of the lung-mimicking structure is constructed with liquid hydrogel, and solidified using light.

The new study stands out in its sheer creativity. By combining organoids with an ancient sculpture technique, the team was able to pack far more cells into the resulting structure, while tapping into the natural mini-organization that stems from organoids. The results arent just promising for printing larger, more intricate human organs with a blood supplythey could also help inform organoid research, which has struggled to keep the pseudo-organs alive.

The team is planning to transplant their SWIFT tissue into animals to further examine their function and health. But to the team, the main goal is to finally bring 3D-printed organs to people desperately on the transplant waiting list.

Our method opens new avenues for creating personalized organ-specific tissues with embedded vascular channels for therapeutic applications, they said.

Image Credit: Wyss Institute at Harvard University / CC BY-NC-ND 4.0

Read the original post:
How a Centuries-Old Sculpting Method Is Helping 3D Print Organs With Blood Vessels - Singularity Hub

BIOLIFE4D Successfully 3D Bioprints a Miniature Human HeartOne Step Closer to Bioprinting Transplantable Organs – BioSpace

Bioprinting is a type of 3D printing to manufacture biological. So far, the process has been used to develop organs or organoidssmaller versions of organs that are at least partially functionaland can be used as models for research. Ultimately researchers hope they can bioprint organs that can be used for transplants.

Chicago-based BIOLIFE4D recently bioprinted a 3D miniature human heart, which they say is a big step toward producing a full-sized human heart that could be used for transplant. The company has research facilities at JLABS in Houston.

The miniature heart had all the structures of a full-sized heart, with four internal chambers. The company says it is as close as anyone has gotten to a fully functioning heart via 3D bioprinting.

We are extremely proud of what we have accomplished, from the ability to 3D bioprint human cardiac tissue last summer to a mini heart with full structure now, said Ravi Birla, the companys chief science officer. These milestones are a testament to the hard work of our team and the proprietary process we have developed that enables this type of scientific achievement. We believe we are at the forefront of whole heart bioengineering, a field that has matured quickly over the last year, and well positioned to continue our rapid scientific advancement. Today is an exciting day, but we continue forward earnestly toward the end goal of 3D bioprinting whole human hearts.

3D printing is sometimes called additive manufacturing. It is a way of making three-dimensional solid objects from a digital file. In many ways, the only limitations are the limits on the complexity of the design. 3D printing used in industrial applications typically use carbon fiber as a source material. But bioprinting uses a variety of biological materials, such as single cell suspensions, as the source materials.

In the case of BIOLIFE4Ds heart, they developed a proprietary bioink with a unique composition of different extracellular matrix compounds. These compounds are very similar to the properties of a mammalian heart. The company also developed a novel bioprinting algorithm made up of printing parameters optimized for the whole heart, which it coupled with patient-derived cardiomyocytes. Although the heart is small in size, it has many of the features of a human heart.

BIOLIFE4D isnt the only company working in this specific area. In April, researchers at Tel Aviv University successfully printed the first 3D human heart. The research team used the patients own cells and various biological materials such as collagen and glycoprotein. Their work was published in the journal Advanced Science.

This heart is made from human cells and patient-specific biological materials, stated Tal Dvir, lead researcher. In our process these materials serve as the bioinks, substances made of sugars and proteins that can be used for 3D printing of complex tissue models. People have managed to 3D-print the structure of a heart in the past, but not with cells or with blood vessels. Our results demonstrate the potential of our approach for engineering personalized tissue and organ replacement in the future.

Dvir and his team began by taking biopsies of fatty tissues from the omentum, a fold of visceral peritoneum that hangs from the stomach, in the abdomen of humans and pigs. They then separated the cellular materials from extraneous materials and reprogrammed the cellular materials to become pluripotent stem cells. From these, they were able to develop all three body layers that had the potential to produce any cell or tissue in the body.

They then built an extracellular matrix from collagen and glycoproteins into a hydrogel using the bioprinter. They mixed the cells with the hydrogel, which were then differentiated into cardiac or endothelial cells. This created what theyre calling patient-specific, immune-compatible cardiac patches complete with blood vessels.

From that point, they then created an entirebut smallbioengineered and bioprinted human heart.

Last year, Poietis, a Pessac, France-based company, along with Prometheus, a division of Skeletal Tissue Engineering at Leuven, Belgium, announced they had entered into a two-year Collaborative Research Agreement to develop high-precision 3D Bioprinting of tissue engineered Advanced Therapeutic Medicinal Products (ATMPs) for skeletal regeneration.

Prometheus focuses on tissue-engineered ATMPs with a focus on skeletal regeneration. Poietis is interested in using 3D bioprinting of single cell suspensions into large, patterned tissue structures, especially the laser-assisted bioprinting of multicellular micro-aggregates embedded in bioinks for the formation of layered cellular structures.

What this comes down to is a collaboration to print bone that can be used in transplants or other orthopedic, musculoskeletal or spine-related applications.

Poietis already has a product on the market, Poieskin, a human full thickness skin model produced entirely by 3D bioprinting. It is made up of a dermal compartment composed of primary human fibroblasts embedded in a collagen I matrix overlaid by a stratified epidermis derived from primary human keratinocytes.

In May, researchers with Rice University developed a new approach resulting in exquisitely entangled vascular networks that mimic the bodys natural passageways for blood, air, lymph and other vital fluids. The research was published in the journal Science.

One of the biggest roadblocks to generating functional tissue replacements has been our inability to print the complex vasculature that can supply nutrients to densely populated tissues, stated Jordan Miller of Rice University. Further, our organs actually contain independent vascular networkslike the airways and blood vessels of the lung or the bile ducts and blood vessels in the liver. These interpenetrating networks are physically and biochemically entangled, and the architecture itself is intimately related to tissue function. Ours is the first bioprinting technology that addresses the challenge of multivascularization in a direct and comprehensive way.

Also in May, San Diego-based Organovo entered a collaboration agreement with Melissa Little at the Murdoch Childrens Research Institute (MCRI), The Royal Childrens Hospital, in Melbourne, Australia, and Ton Rabelink at Universiteit Leiden (LUMC), Leiden, Netherlands. The collaboration will focus on expanding the use of 3D bioprinted stem cell-based therapeutic tissues. The goal is to develop treatments for end-stage renal disease.

The collaboration will utilize Organovos bioprinting platform, MCRIs advanced stem cell differentiation technology, and LUMCs cell lines and clinical expertise. The partnership is funded by Stem Cells Australia and CSL Limited.

And in 2018, United Therapeutics and Lung Biotechnology made a collaboration pact with Israeli 3D bioprinting company CollPlant. United paid CollPlant $5 million up front with up to $15 million in milestones to supply bioink to Lung Biotechnology. CollPlants recombinant human collagen (rhCollagen) is grown from tobacco plants engineered with five human genes. The purified collagen can be used as a scaffold for 3D bioprinting solid organs.

BIOLIFE4D has had several breakthroughs in this area. Earlier this year it successfully 3D bioprinted individual heart components, and in June 2018 it successfully 3D bioprinted a cardiac patch out of human cardiac tissue.

The companys 3D bioprinting process gives the researchers the opportunity to reprogram a patients own white blood cells to induced pluripotent stem (iPS) cells, then to force the iPS cells to differentiate into different types of cardiac cells to be used as individual cardiac components and eventually, into a human heart that could be used for transplant.

This is an incredibly exciting time for BIOLIFE4D, and we are so proud of Dr. Birla and the team for this tremendous accomplishment, said Steven Morris, the companys chief executive officer. We began this journey with an end goal of developing a technology that has the potential to save lives, and we are a step closer to that today. We will continue our work until we are able to 3D bioprint full-sized hearts for viable transplant, and change the way heart disease is treated forever.

Read more:
BIOLIFE4D Successfully 3D Bioprints a Miniature Human HeartOne Step Closer to Bioprinting Transplantable Organs - BioSpace

Study indicates early infusion of mononuclear cells could aid in recovery from stroke – Yahoo Finance

Results of a clinical trial published today in STEM CELLS are the first to document the safety and feasibility of the early administration of bone marrow cells to treat acute ischemic stroke patients.

DURHAM, N.C., Sept. 17, 2019 /PRNewswire-PRWeb/ --Results of a clinical trial published today in STEM CELLS are the first to document the safety and feasibility of the early administration of bone marrow cells to treat acute ischemic stroke patients. The information provided by the study could aid in developing new cellular therapies for this most common form of stroke caused by a blocked artery which affects over 13 million people each year, according to the World Health Organization.

The study in STEM CELLS is a follow up to the initial report on the first 10 patients in the trial, published in the Annals of Neurology in 2011. The STEM CELLS paper represents the total group of 25 patients.

Sean Savitz, M.D., director of the Institute for Stroke and Cerebrovascular Disease and professor of neurology at McGovern Medical School at UTHealth Houston, was lead investigator on the study. "Having found no clear evidence of harm to the initial 10 patients," he said, "we broadened the inclusion criteria and enrolled additional patients. Our choice of cell type bone marrow mononuclear cells (BM MNCs) dose (10 million cells/kg), timing; route of administration; and the autologous approach was based on, and is in line with, growing evidence from animal stroke models and clinical evidence for possible treatment effects in our traumatic brain injury studies and other diseases."

BM MNCs are attractive in regenerative medicine studies because they can be rapidly isolated; are enriched with hematopoietic, mesenchymal and endothelial progenitor cells; and permit autologous applications. Preclinical studies consistently indicate that MNCs improve outcome when administered within 72 hours of stroke onset and at least one clinical trial has shown they are not effective beyond seven days, the researchers said.

The regenerative potential of BM-derived MNCs is attributed to various mechanisms that impact stroke recovery. The cells migrate to the site of injury, release cytokines and other trophic factors, decrease proinflammatory and upregulate anti-inflammatory pathways, among other things. They also are easily amenable to autologous infusion, eliminating the need for immunosuppressive drugs.

"In contrast to the generation of autologous mesenchymal stem cells, another promising cell therapy," added Dr. Savitz, "MNCs do not require passage in culture, which allows for testing in the early post-stroke time window."

Each patient in the Savitz team's study received an intravenous dose of their own BM MNCs within 72 hours after onset of their stroke. They were then followed for one year after treatment and the results compared to a control group of 185 acute ischemic stroke patients who received conventional treatment only. No definite severe adverse events related to the procedures were seen in any of the 25 patients, the research showed.

"In the light of our findings," said Dr. Savitz, "we believe that MNCs pose no additional harm in ischemic stroke patients when given during the acute phase, doses up to 10 million cells/kg are tolerated and it is feasible to perform a BM harvest and re-infusion of MNCs for a wide range of stroke patients. Well-designed random clinical trials are needed to further assess safety and efficacy of this novel approach to enhance stroke recovery."

"New options to treat Ischemic stroke are desperately needed," said Dr. Jan Nolta, Editor-in-Chief of STEM CELLS. "This important clinical trial provides solid safety and feasibility data on which later trials can be built, using the patient's own bone marrow stem/progenitor cells to potentially enhance recovery after ischemic stroke."

The full article, "Intravenous Bone Marrow Mononuclear Cells for Acute Ischemic Stroke: Safety, Feasibility, and Effect Size from a Phase I Clinical Trial," can be accessed at https://stemcellsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/stem.3080.

About the Journal: STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. The journal covers all aspects of stem cells: embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; cancer stem cells; the stem cell niche; stem cell epigenetics, genomics and proteomics; and translational and clinical research. STEM CELLS is co-published by AlphaMed Press and Wiley.

Story continues

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes three internationally renowned peer-reviewed journals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines. STEM CELLS (http://www.StemCells.com) is the world's first journal devoted to this fast paced field of research. THE ONCOLOGIST (http://www.TheOncologist.com) is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. STEM CELLS TRANSLATIONAL MEDICINE (http://www.StemCellsTM.com) is dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.

About Wiley: Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical and scholarly journals, combined with our digital learning, assessment and certification solutions, help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at http://www.wiley.com.

View post:
Study indicates early infusion of mononuclear cells could aid in recovery from stroke - Yahoo Finance

Scientists recognize genes as master regulators in schizophrenia – Tech Explorist

Schizophrenia is a chronic and severe mental disorder that influences how a person thinks, feels, and carries on. People with schizophrenia may appear as though they have lost touch with reality.

It is a debilitating neuropsychiatric disease that affects about 1% of adults with heritability ranging from 73 to 83% in twin studies. However, its underlying genetic architecture remains incompletely understood.

Kai Wang, Ph.D., of the Department of Pathology and Laboratory Medicine said, Because hundreds, or even thousands, of genes, may contribute to the risk of schizophrenia, it is crucial to understand which are the most important ones, orchestrating core networks in the disease.

In a new study by the Childrens Hospital of Philadelphia (CHOP), scientists used computational tools to determine the gene transcription networks in extensive collections of brain tissues and investigated a gene that acts as a master regulator of schizophrenia during early human brain development.

Scientists used computational systems biology approaches to discern a disease-relevant core pathway in schizophrenia and to discover a master regulator in that pathway that affects hundreds of downstream genes.

Scientists analyzed two different datasets of biological samples from schizophrenia patients and control subjects. One dataset, the CommonMind Consortium (CMC), is a public-private partnership with well-curated brain collections. The other was a collection of primary cultured neuronal cells derived from olfactory epithelium (CNON), generated by study co-authors at the University of Southern California and SUNY Downstate.

The CMC dataset contained adult postmortem brain tissue, while the CNON dataset, used to validate findings from the CMC study, represented cell cultures that contain neuronal cells from nasal biopsies.

Applying an algorithm developed at Columbia University to reconstruct gene transcription networks, the study team identified the gene TCF4 as a master regulator for schizophrenia.

Wang said, Previous genome-wide association studies (GWAS) had indicated that TCF4 was a locus for schizophrenia risk, but little was known of the genes functional effects. We investigated those effects by knocking down, or decreasing, the genes expression in neural progenitor cells and glutamatergic neurons derived from induced pluripotent stem cells in Duans lab at NorthShore.

Observations on three different cell lines showed that, when knocked down, the predicted TCF4 regulatory networks were enriched for genes exhibiting transcriptomic changes, as well as for genes involved in neuronal activity, schizophrenia risk genes having genome-wide significance, and schizophrenia-associated de novo mutations.

Jubao Duan, Ph.D., the Charles R. Walgreen Research Chair and an associate professor at the Center for Psychiatric Genetics of North Shore University HealthSystem (NorthShore) said, The results from perturbing TCF4 gene networks in human stem cell models may be more relevant to the neurodevelopmental aspects of neuropsychiatric disorders.

The study represents one of the first successful examples of combining computational approaches and stem cell-based experimental models to disentangle complex gene networks in psychiatric diseases.

The study is published in the journal Science Advances..

View original post here:
Scientists recognize genes as master regulators in schizophrenia - Tech Explorist

Japanese lab to collaborate with Christian Dior in iPS cell research – Japan Today

An iPS cell research center at one of Japan's top universities said said Thursday that it has entered into a collaborative research project to explore skin rejuvenation with the perfumery and cosmetics division of luxury French fashion house Christian Dior SE.

The Center for iPS Cell Research and Application at Kyoto University, a leading center for induced pluripotent stem cell research, will work with Parfums Christian Dior to analyze what factors are linked to certain signs of aging, such as wrinkles, by comparing the state of skin cells generated from the iPS cells of young and elderly donors.

In the future, the project will also investigate what substances are necessary for regeneration, and how skin cells change after being subjected to various everyday stresses, such as ultraviolet radiation and heat.

Dior Science, the research arm of the luxury brand, has for the past 20 years been exploring how skin cells transform with age and has made a series of discoveries in the cutaneous domain. It aims to utilize the center's stem cell technology to develop ways of regenerating skin cells and maintaining youthful skin.

The collaborative project also hopes to investigate the effects of advancing age on the status of mitochondria, which creates energy for cells, and conduct research using the laboratory's expertise on genome editing.

The center continues to conduct innovative research on the medical applications of iPS cells, which can be converted into any type of cell in the body, including regenerative medicine and the development of new drugs.

Link:
Japanese lab to collaborate with Christian Dior in iPS cell research - Japan Today

Induced Pluripotent Stem Cell Market Research Report 2019 From TBRC has Been Updated – Market Research Gazette

A recent report published by The business research Company on Induced Pluripotent Stem Cell (IPSC) Market provides in-depth analysis of segments and sub-segments in the global as well as regional market.

The induced pluripotent stem cell (IPSC) market is a segment of the healthcare services market. The report will answer questions such as where the largest and fastest growing market is, how the market relates to the overall economy, demography and other similar markets, and what forces will shape the market going forward.

The induced pluripotent stem cell (iPSC) market consists of sales of induced pluripotent stem cells and related services. Induced pluripotent stem cells are the regenerated form of stem cells, which are produced from an existing adult cell, such as from hepatocytes, fibroblasts, keratinocytes and neurons.

View complete Report: https://www.thebusinessresearchcompany.com/report/induced-pluripotent-stem-cell-ipsc-global-market-report

Increase in the prevalence of chronic disorders is one of the major factors that is driving the growth of Induced pluripotent stem cell market. Chronic disorders like heart disease, cancer, stroke, diabetes can be treated with Induced pluripotent stem cell. Induced Pluripotent stem cells are taken from any tissues from a child or an adult and are genetically modified to behave like embryonic stem cells.

The potential risk of tumor is one of the major restraints on the growth of Induced pluripotent stem cell market. As per a scientific research, it was found that there might be a chance of getting cancer from the treatment and people are unwilling to take treatment through Induced pluripotent stem cell therapy.

Request a Sample Report At: https://www.thebusinessresearchcompany.com/sample.aspx?id=2515&type=smp

Few Points From Table Of Content

.

Browse our latest Press Release on website @ https://www.thebusinessresearchcompany.com/press-release.aspx

About The Business Research Company:

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.

Contact Information:

The Business Research Company

https://www.thebusinessresearchcompany.com

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: [emailprotected]

Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company

Originally posted here:
Induced Pluripotent Stem Cell Market Research Report 2019 From TBRC has Been Updated - Market Research Gazette

Religion briefs for Sept. 19 | Community – Petoskey News-Review

Church to host food summit

PETOSKEY More than 6,500 people (11 percent) of Charlevoix and Emmet counties live at or below the poverty level.

In response to this need, dozens of churches and organizations host food pantries and/or offer free community meals throughout the week.

Emmanuel Episcopal Church, 1020 E. Mitchell St., Petoskey, is hosting a food summit from 9 a.m.-noon Saturday, Sept. 28, to bring individuals, churches and organizations together who are passionate about supporting people who are experiencing food insecurity to share best practices and learn about opportunities for collaboration.

Kim Baker, executive director of Manna Food Project, is the keynote speaker. Manna Food Project partners with food pantries, community meal programs and baby/paper pantries throughout Emmet, Charlevoix and Antrim counties.

In addition, there will be workshops on best practices in operating food pantries, community meals and grant writing.

Members of the community are invited to attend this summit, whether you are already involved in a food-based ministry or initiative, or if you would like to learn how you might become involved.

If you are interested in attending the summit or seeking more information, contact the Emmanuel Episcopal Church office at (231) 347-2350.

Community breakfast offered

ALANSON There will be a community breakfast from 9:30-10:45 a.m. Sunday, Sept. 22, at the Alanson Church of the Nazarene, 7489 Mission Road.

The meal is free of charge and features biscuits and gravy, scrambled eggs, waffles, juice and coffee.

There also will be face painting for the kids.

The breakfast is sponsored by the churchs Sunday School.

For more information, call the church at (231) 548-5462.

Stem cell therapies discussed

BOYNE CITY A discussion about stem cell therapies will begin at 6:30 p.m. Sunday, Sept. 22, at Lifetree Caf.

The program, Stem Cells: The Miracle Cure You May Be Missing Out On, includes a film featuring a regenerative stem cell procedure as well as an interview with Dr. Christopher Centeno, who performs orthopedic procedures using adult stem cells in both the U.S. and in an offshore clinic.

Over the next 20 to 30 years, many drugs we use today will be replaced by stem cells from our own bodies, or cells mass-produced in labs, said Centeno, who notes that the shift in medicine puts at risk much of the $300 billion prescription drug market.

Centeno, who uses stem cells as an alternative to joint replacement and to treat tendon, ligament and bone pain, wonders if concerns about lost revenue have prompted the domestic ban of some procedures that are available in other countries. This program provides insights into the ongoing debate.

The hourlong program is free of charge.

Lifetree Caf is in the First Presbyterian Church, 401 S. Park St. Use the Pine Street entrance.

Creation at Risk sermon topic

CHARLEVOIX Greensky Hill Indian United Methodist Church, 08484 Green Sky Hill Road, presents part four in the five-week series, The Season of Creation.

At 10 a.m., Sunday, Sept. 22, the Rev. Jonathan Mays will share a message from Jeremiah 8:18-9:1 entitled, Creation at Risk.

Mark the date for the finale of the series on Sunday, Sept. 29, when the community is invited to bring leashed or caged animals for The Blessing of the Animals ceremony at Greensky Hills outdoor worship space, The Tabernacle.

Also, Greensky Hills annual harvest dinner will be from 4-6:30 p.m., Saturday, Sept. 28, in Susan Hall.

All are welcome for a traditional menu including turkey, mashed potatoes and gravy, stuffing, squash, ham, corn, carrots, string beans, creamed cabbage, applesauce, tomatoes, dinner rolls, pie, coffee, tea and lemonade.

The cost is $12 for adults; $4 for children ages 4-12; and $35 for a family of six or more.

Message looks at anger, harsh words

CHARLEVOIX On Sunday, Sept. 22, the series, Braving the Wilderness, continues at Community Reformed Church.

The title of the message is Carried Anger and Harsh Words and will be based on Matthew 5:21-22.

Sunday morning services are at 8:30 and 10:15 with nursery available at each service.

Worship activities for children preschool through fourth grade are offered during the 10:15 service.

The church is located at 100 Oak St.

Read more:
Religion briefs for Sept. 19 | Community - Petoskey News-Review